Compare Sana Biotechnology Inc (SANA) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Toyota Motor Corp — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Toyota Motor Corp trades at $185.3 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 259.8× Sana Biotechnology Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Toyota Motor Corp for 116 Days on average.
| SANA | TM | |
|---|---|---|
Market Cap | $836.71M | $217.38B |
Volume | 4,507,444 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $248.29 |
52-Week Low | $2.68 | $166.50 |
Typical Hold Time | 23 Days | 116 Days |
Enterprise Value | $749.96M | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Toyota Motor trades at $186.00, up 1.69% with strong fundamentals including a low P/E of 8.38 and consistent earnings beats. The stock faces technical headwinds with a bearish signal and declining profit margins, though recent U.S. sales growth and electrification investments provide momentum. Cash flow trends show volatility with a negative net cash flow of -$429.66 billion in 2025, but projected improvement to $2.25 trillion in 2026.
Toyota presents a value opportunity with attractive valuation metrics and market leadership, but investors must weigh declining China sales, production disruptions from Thailand floods, and competitive pressures. Analyst consensus leans cautious with 62.5% hold ratings, suggesting patience for margin recovery and electrification execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
